Clinical update: Proteasome inhibitors in solid tumors

Cancer Treatment Reviews

Volumn 29, Issue SUPPL. 1, 2003, Pages 41-48

  Lenz, Heinz Josef ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Anti angiogenesis; Apoptosis; Bortezomib; Proteasome inhibitor; Solid tumors; Tumor inhibition

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ANTINEOPLASTIC AGENT; BORTEZOMIB; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IRINOTECAN; LOPERAMIDE; PACLITAXEL; PROTEASOME; PROTEASOME INHIBITOR; PROTEIN P21; PROTEIN P27; PROTEIN P53; UNCLASSIFIED DRUG;

ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BLOOD TOXICITY; BREAST TUMOR; CANCER GROWTH; CANCER INHIBITION; CELL CYCLE; CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENTIATION; DRUG SCREENING; ENZYME DEGRADATION; ENZYME INHIBITION; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; LUNG TUMOR; MALE; METASTASIS; NAUSEA AND VOMITING; NEUTROPENIA; OVARY TUMOR; PANCREAS TUMOR; PROTEIN FUNCTION; PROTEIN STABILITY; REVIEW; SENSORY NEUROPATHY; SIDE EFFECT; SOLID TUMOR; THROMBOCYTOPENIA; TUMOR VASCULARIZATION;

EID: 0037514596     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0305-7372(03)00082-3     Document Type: Review

References (30)

1. Adams J, Palombella VJ, Sausville EA, et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 1999; 59(11): 2615-2622.
2. Adams J, Palombella VJ, Elliott PJ. Proteasome inhibition: a new strategy in cancer treatment. Invest New Drugs 2000; 18(2): 109-121.
3. Maki CG, Huibregtse JM, Howley PM. In vivo ubiquitination and proteasome-mediated degradation of p53(1). Cancer Res 1996; 56(11): 2649-2654.
4. Read MA, Neish AS, Luscinskas FW, et al. The proteasome pathway is required for cytokine-induced endothelial - leukocyte adhesion molecule expression. Immunity 1995; 2(5): 493-506.
5. Sunwoo JB, Chen Z, Dong G, et al. Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappaB, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin Cancer Res 2001; 7(5): 1419-1428.
6. Teicher BA, Ara G, Herbst R, et al. The proteasome inhibitor PS-341 in cancer therapy. Clin Cancer Res 1999; 5(9): 2638-2645.
7. Cusack Jr JC, Liu R, Houston M, et al. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition. Cancer Res 2001; 61(9): 3535-3540.
8. Shah SA, Potter MW, McDade TP, et al. 26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer. J Cell Biochem 2001; 82(1): 110-122.
9. Bold RJ, Virudachalam S, McConkey DJ. Chemosensitization. of pancreatic cancer by inhibition of the 26S proteasome. J Surg Res 2001; 100(1): 11-17.
10. Pink M, Pien CS, Worland P, et al. PS-341 enhances chemotherapeutic effect in human xenograft models. Proc Am Assoc Cancer Res 2002; 43: 158.
11. Aghajanian C, Soignet S, Dizon DS, et al. A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin Cancer Res 2002; 8(8): 2505-2511.
12. Papandreou C, Daliani D, Millikan RE, et al. Phase I study of intravenous (I.V.) proteasome inhibitor PS-341 in patients (Pts) with advanced malignancies. In: Proceedings of the American Society of Clinical Oncology - 37th Annual Meeting, vol. 20; 2001. p. 86a.
13. Hamilton AL, Eder J, Pavlick AC, et al. PS-341: Phase I study of a novel proteasome inhibitor with pharmacodynamic endpoints. In: Proceedings of the American Society of Clinical Oncology - 37th Annual Meeting, vol. 20; 2001. p. 85a.
14. Clark JW, Ryan D, Dees C, et al. Phase I dose-escalation study of the proteasome inhibitor, PS-341, plus irinotecan in patients with advanced solid tumors. In: Proceedings of the American Society of Clinical Oncology - 38th Annual Meeting, vol. 21; 2002. p. 93a.
15. Ryan DP, Eder JP, Winklemann J, et al. Pharmacokinetic and pharmacodynamic phase I study of PS-341 and gemcitabine in patients with advanced solid tumors. In: Proceedings of the American Society of Clinical Oncology - 38th Annual Meeting, vol. 21; 2002. p. 95a.
16. Iqbal S, Lenz H-J, Groshen S, et al. Phase I study of PS-341 in combination with 5-FU/LV in solid tumors. Proceedings of the American Society of Clinical Oncology - 38th Annual Meeting, vol. 21; 2002. p. 93a.
17. Pagano M, Tam SW, Theodoras AM, et al. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 1995; 269(5224): 682-685.
18. Yatabe Y, Masuda A, Koshikawa T, et al. p27KIP1 in human lung cancers:differential changes in small cell and non-small cell carcinomas. Cancer Res 1998; 58(5): 1042-1047.
19. Esposito V, Baldi A, De Luca A, et al. Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer. Cancer Res 1997; 57(16): 3381-3385.
20. Kamat AM, Karashima T, Dinney CP, McConkey DJ. The proteasome inhibitor PS-341 sensitizes drug-refractory human transitional cell tumors to gemcitabine. Proc Am Assoc Cancer Res 2002; 43: 157.
21. Thornton JD, Liu, R, Orlowski, RZ, et al. Doxorubicin-induced NF-kappaB activation in breast cancer is overcome by proteasome inhibition, resulting in enhanced tumoricidal response to treatment. Presented at the 87th Annual Clinical Congress of the American College of Surgeons, New Orleans, LA, October 7-12; 2001.
22. Russo SM, Tepper JE, Baldwin AS, et al. Enhancement of radiosensitivity by proteasome inhibition:implications for a role of NF-κB. Int J Radiat Oncol Biol Phys 2001; 50(1): 183-193.
23. Chen Z, Malhotra PS, Gill R, et al. Identification of sensitive and resistant head and neck squamous cell carcinoma lines to PS-341, a novel anti-cancer agent inhibiting proteasome dependent activation of NF-κB. Proc Am Assoc Cancer Res 2002; 43: 158.
24. Ling YH, Jiang J-D, Liebes L, et al. Molecular mechanisms of proteasome inhibitor PS-341-induced G2/M phase arrest and apoptosis in human non-small cell lung cancer H460 cells. Proc Am Assoc Cancer Res 2002; 43: 665.
25. Gumerlock PH, Moisan LP, Lau AH, et al. Docetaxel followed by PS-341 results in phosphorylation and stabilization of p27 and increases response in non-small cell lung carcinoma (NSCLC). Clin Cancer Res 2001; 7(11): 157.
26. Frankel A, Man S, Elliott P, et al. Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341. Clin Cancer Res 2000; 6(9): 3719-3728.
27. Nawrocki ST, McConkey DJ. The proteasome inhibitor, PS-341, inhibits the growth of pancreatic cancer cells in vitro and in vivo. Proc Am Assoc Cancer Res 2002; 43: 159.
28. Sclabas GM, Dong QG, Fujioka S, et al. Drug-elicited apoptosis in pancreatic tumor cells: the role of different complexes between IκB and NF-κB. Proc Am Assoc Cancer Res 2002; 43: 882.
29. Per van M, Pajonk F, Sun JR, et al. Molecular pathways that modify tumor radiation response. Am J Clin Oncol 2001; 24(5): 481-485.
30. Williams SA, Papandreou C, McConkey D. Preclinical effects of proteasome inhibitor PS-341 in combination chemotherapy for prostate cancer. In: Proceedings of the American Society of Clinical Oncology - 37th Annual Meeting, vol. 20; 2001. p. 169b.